### **FAX**



Type site code here

To Examiner Richard Raymond, Group Art U: 1624 Company USPTO Fax 571 273-0673 From Lorie Ann Morgan Tel / Fax 919 483-8222 / 919 483-7977 Lorie.A.Morgan@gsk.com E-mail Date 21-Oct-2004 Pages including cover 6 Subject USSN 10/089,964

Serial No. 10/089,964
Filing Date: 8 May 2002
Applicant: Alvaro et al.
Title: Chemical Compounds

Attached: Copy of IDS and PTO-1449 filed 18 May 2004 and confirmation of receipt by PTO.

Dear Ex. Raymond,

Attached for your consideration is a copy of the IDS and PTO-1449 filed 18 May 2004 together with confirmation of receipt by the PTO. Kindly consider the reference identified on the PTO-1449 in connection with the above-referenced patent application and return an initialed copy of the PTO-1449 at your earliest convenience. I would be grateful to receive the initialed PTO-1449 before the due date for filing the issue fee.

Applicants also respectfully request favorable consideration of the Petition to Change Inventorship, filed on 15 June 2004.

Thank you for your assistance in this case and please do not hesitate to contact me should you require anything further.

Sincerely,


Lorie Ann Morgan Reg. No. 38,181 Attorney for Applicants

GlaxoSmithKline phone: 919 483-8222

fax: 919 483-7977

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

## FAX



**gsk** GlaxoSmithKline

> Glaxo Wellcome Inc. PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

Serial No.: 10/089,964
Filing Date: May 8, 2002
Applicant: Alvaro et al.
Title: Chemical Compounds

Attached: Transmittal Form w/Certificate of transmission via facsimilie Supplemental IDS PTO1449 1 Reference

Thank you, Valerie Phillips

#### Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on May 18, 2004.

Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

#### **PI3806USW**

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alvaro et al.

Serial No.:

10/089,964

Group Art Unit: 1624

File Date:

May 8, 2002

Examiner:

R. Raymond

For:

Chemical Compounds

Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandría, VA 22313-1450

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[ ] Co	opies of the references are enclosed:  opies of the references were submitted in parent application Scrial No (37 CFR 1.98(d))  copy of the International Scarch Report which issued on International Application No is  bmitted herewith. All of the publications cited in the International Search Report are listed on the  tached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent  ffice by the International Bureau.				
A.	[]	filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).				
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).				
B.	[X]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first				
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.				
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(e) (\$180.00).				
C.	[ ]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.				

In accordance with the requirements of 37 CFR 1.97(d):

#### PI3806USW

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The position fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 5/18/04 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

# **Auto-Reply Facsimile Transmission**



TO:

Fax Sender at 919 483 5730

Fax Information Date Received: Total Pages:

5/18/2004 10:21:55 AM [Eastern Daylight Time]

18 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page

VAT. 19, 2004	10-598H GN 010381 843 18	но, веве 7 1						
		जब <i>े</i>						
FAX		GlaxoSmith dine						
Ta	Alun: Group Art Unit 1524	Claim William with						
Compa	y USPYO	Paro Mg wa Daka Masanah Transpo Park Masa Sarahas 2775						
Fax	709-872-8306	7±: \$14 483 ≥100 ******						
Feam	Valente L. Philips							
Tel	979-443-8223 Fax 919-488-6730							
E-mali	Y847157(Best 047)							
Date Subjec	May 18, 2004 Pages Inchaling 50400 19	•						
Algodie Transit Supple PTO14	Filing Date: May 8, 2002 Applicants Alvaro et al. Title: Chunical Compounds Alached: Transmittel Form viCentificate of transmission via fescintile Supplemental TDS PTO 1448 1 Reference							
Thank Vojerič	you. Phillips							
Çenî	paths of Transmission by Secounts (37 CFR 1.0)	on one illustrat Physics Botton) and						
\/\ <u>0</u>	y sermy that this Supplemental \$16 is being incaimle re-hamited yer. Carlos (Fex. 319, 705-672-9306) on May 16, 2004.	and the problem of the party of the party of the						
The bid actions pays anys	iornamiem genininki in Peres discorregió is considera el ape, vez ales en pre-legad e 194 denigrajad abbre il redu en reis ne inhandat registra el tila geninistra il ved 195 denigrajad abbre il redu en reis ne inhandat registra el tila de 195 denigrajad abbre il resultado de l'archivion, el registra della considerazioni si della del 195 denigrajad della considerazioni in serve piccare quebad del interpolitado pi le implea a all Di	and is indended for the ancisy we said of the off teleprophic to do from it is the hymotophic is, economication in muschy with abilities, if you all you call distings for the season.						
	ana servaluti am servano prografo Timoli Cisti del Bito Citto Citt	udda con cross south first home and 67.00						

Page 1 of 1

FORM PTO-1 INFORMATION	449 ON DISCLOSURE ST	ratement	P13806USW			SERIAL NO. 10/089,964	
				APPLICANT: Alvero et al.			
			FILING DATE:		GROUP 1624		
		rre b	May 8, 2002 ATENT DOCUMENTS		1024		
Examiner Initials	Patent	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
7,7	Number	27 10.1006	Gonselves et al.	E'id	231.2		
1715	5,576,317	Nov. 19, 1996	Consulves et al.	514	<del>- 221, 2-</del>	<del> </del>	
<u> </u>		<del></del>			<del> </del>	<del> </del>	
						<del>                                     </del>	
		<del></del>			<del></del>		
		<u></u>			<del> </del>	<del> </del>	
		<del></del>			<del></del>	<del>                                     </del>	
		<del></del>					
		· <del> </del>				1	
		Co	ntinuc on page			<b></b>	
			N PATENT DOCUMENTS	3			
	Document	Publication	, <u>, , , , , , , , , , , , , , , , , , </u>			Translation	
	Number	Date	Country	Class	Subclass	Yes   No	
						<b></b>	
						<b>.</b>	
						<b></b>	
					ļ	ļ_ <del></del>	
						ļ	
					<del></del>	<del> </del>	
					<del></del>	-	
				,		<u> </u>	
		Co	ntinue on page	371			
	OTHER DOCU	MENTS (Includia	g Author, Title, Journal-D	late, Page Numi	er, Etc.)		
		·		<del></del>			
<b>├</b> ───┼							
<del>                                     </del>							
<del>                                     </del>							
<del></del>				· · · · · · · · · · · · · · · · · · ·			
<del></del>	<del></del>						
} <del></del>	<del></del>						
<del> </del>		1					
<del></del>		<del>-</del> /c	ontinue on page				
EXAMINER		442004			CONSIDERED	ι <u>/</u>	
PYAMINED.	Initial if citation consider	dered, whether or n	ot citation is in conformance	with MPEP § 6	09; Draw line th	rough citation	
if not in confor	mance and not conside	red. Include copy	of this form with next comm	unication to the	applicant.		